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Abstract
Background: We found recently that baseline signal transducer and activator of transcription 3 phosphorylation in
peripheral blood CD4+ T cells of patients with early rheumatoid arthritis (RA) is associated with treatment response
to synthetic disease-modifying antirheumatic drugs (DMARDs). This prompted us to study the baseline
phosphorylation profiles of Janus kinases (JAKs) in blood leukocytes with respect to treatment response in early RA.
Methods: Thirty-five DMARD-naïve patients with early RA provided blood samples for whole blood flow cytometric
determination of phosphorylation of JAKs in CD4+ and CD8+ T cells, CD19+ B cells, and CD14+ monocytes.
Treatment response was determined after 1 year of treatment with synthetic DMARDs, with remission defined as
absence of tender and swollen joints and normal erythrocyte sedimentation rate. Exact logistic regression was used
to investigate the association of baseline variables with treatment response. Ninety-five percent CIs of means were
estimated by bias-corrected bootstrapping.
Results: High JAK3 phosphorylation in CD4+ and CD8+ T cells, CD19+ B cells, and CD14+ monocytes and low JAK2
phosphorylation in CD14+ monocytes were significantly associated with remission following treatment with
synthetic DMARDs.
Conclusions: Baseline JAK phosphorylation profile in peripheral blood leukocytes may provide a means to predict
treatment response achieved by synthetic DMARDs among patients with early RA.
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Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by inflammatory synovitis; articular
destruction; extra-articular manifestations; and, when
not responding to treatment satisfactorily, progressive
disability and increased mortality. The disease is hetero-
geneous, and its pathogenetic mechanisms are not clear,
but they are known to involve both genetic and environ-
mental factors as well as innate and adaptive immunity
[1]. Synthetic disease-modifying antirheumatic drugs
(sDMARDs) are the first treatment option in untreated
RA, used either as monotherapy or in various combina-
tions [2–4]. Recently, highly selective immunological
agents have been developed for the treatment of RA, in-
cluding biological disease-modifying antirheumatic drugs
(DMARDs), especially blockers of inflammatory cyto-
kines and immune cell surface receptors [5], and agents
inhibiting intracellular signal transduction pathway
members. As to the latter, Janus kinases (JAKs) are
tempting targets because they are required for classical
immune cytokine receptor signal transduction and con-
sequently are involved in the pathophysiology of several
inflammatory and immune disorders [6, 7]. Despite the
multiple drug options for treatment of RA, the lack of
reliable predictive biomarkers poses a challenge to find-
ing the most effective and suitable treatment for each in-
dividual rapidly, preferably within 3–4 months from the
onset of symptoms [8].
A few years ago, we started to study the phosphoryl-
ation of the signal transducer and activator of transcrip-
tion (STAT) transcription factors as biomarkers of
disease activity and treatment response in RA [9]. We
found that baseline phosphorylation of STAT3 in whole
blood leukocytes is associated with the treatment re-
sponse achieved by use of sDMARDs [10]. In the present
study, we made progress in studying the JAK-STAT
pathway and aimed at elucidating if JAK phosphoryl-
ation levels are able to distinguish DMARD-naïve pa-
tients with RA who will respond well to sDMARDs from
those who will require still other treatment options.
Using a phosphospecific whole blood flow cytometric
method, we measured the baseline phosphorylation
levels of all known JAKs (i.e., JAK1, JAK2, JAK3, and
tyrosine kinase 2 [Tyk2]) in whole blood T cells, B cells,
and monocytes of patients with early untreated RA.
Methods
Subjects
The study included 35 patients diagnosed with early RA
at the Division of Rheumatology, Helsinki University
Central Hospital, Helsinki, Finland, between April 2012
and April 2013. The patients fulfilled the American
College of Rheumatology/European League Against
Rheumatism 2010 classification criteria [11]. At study
entry, the patients had received no DMARDs or oral
glucocorticoids. Twenty-one healthy volunteers (62%
women; mean age 47 years [SD 13 years]) with no infec-
tious symptoms or history of autoimmune disease and
derived from hospital and laboratory staff served as ref-
erence subjects. All subjects were white Finnish persons
residing in the Helsinki metropolitan area. The study
protocol was approved by the ethical review board of the
Joint Authority for the Hospital District of Helsinki and
Uusimaa, and written informed consent was obtained
from each patient.
Clinical evaluation
A comprehensive clinical and laboratory evaluation was
undertaken at entry concomitant to blood sampling.
Joints were evaluated for swelling and pain (66 and 68
joints, respectively). Patient global assessment of disease
activity was recorded on a 100-mm visual analogue
scale. Laboratory measurements, including white blood
cell count, erythrocyte sedimentation rate (ESR), and
plasma C-reactive protein (CRP) level, were logged. The
28-joint Disease Activity Score (DAS28) was calculated
[12]. After a mean 12-month follow-up, the patients
were reexamined. Patients with no tender or swollen
joints (68 and 66 joints, respectively) and normal ESR
were considered to be in remission.
Blood samples
At study entry, an 8-ml blood sample was taken by
venipuncture from the antecubital vein into a Falcon
polypropylene tube (BD Biosciences, Bedford, MA,
USA) supplemented with 800 μl of pyrogen-free acid cit-
rate dextrose solution A (ACD-A; Baxter Healthcare
Ltd, Thetford, UK). Cells were prepared for flow cytome-
try within 3 h of blood sampling.
Antibodies
The following antibodies were purchased from BD Bio-
sciences (San Jose, CA, USA): fluorescein isothiocyanate
(FITC)-conjugated anti-CD14 (MφP9), anti-CD4 (SK3),
and anti-CD19 (SJ25C1); phycoerythrin (PE)-conjugated
anti-CD3 (SP34-2); peridinin chlorophyll protein com-
plex (PerCP)-conjugated anti-CD3 (SK7); Alexa Fluor
647-conjugated anti-CD8 (RPA-T8) mouse anti-human
monoclonal antibodies; and PE-conjugated anti-rabbit
secondary antibody. Anti-phosphorylated (anti-p)-JAK1
(PhosphoDetect Tyr1022/1023) rabbit anti-human anti-
body was purchased from EMD Millipore (Darmstadt,
Germany). The following antibodies were purchased
from Santa Cruz Biotechnology (Dallas, TX, USA): anti-
pJAK2 (Tyr1007/Tyr1008), anti-pJAK3 (Tyr980), anti-
pTyk2 (Tyr1054) rabbit anti-human antibodies, and
PerCP-conjugated anti-rabbit secondary antibody. The
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amounts of the antibodies were optimized, and their
compatibility was assured in preliminary examinations.
Preparing leukocytes for flow cytometry
Blood leukocytes were prepared for flow cytometry using
a protocol and buffers by BD Biosciences [13]. Aliquots
(50 μl) of blood were deposited into 12 polystyrene tubes
(BD Biosciences). Four tubes were supplemented with
anti-CD14-FITC, four with anti-CD4-FITC and anti-
CD8-Alexa Fluor 647, and four with anti-CD19-FITC
for surface marker staining of monocytes, CD4+/CD8+ T
cells, and B cells, respectively. Following a 15-minute in-
cubation at 37 °C, leukocytes were fixed and erythro-
cytes lysed by adding 1× Lyse/Fix Buffer (BD
Biosciences). After being pelleted, leukocytes were
permeabilized and washed by incubating them twice in
1× Perm/Wash Buffer (BD Biosciences) at room
temperature protected from light for 15 minutes. Cells
were pelleted and resuspended in Perm/Wash Buffer.
One tube each containing anti-CD14, anti-CD4 and
anti-CD8, and anti-CD19 were supplemented with either
anti-pJAK1, anti-pJAK2, anti-pJAK3, or anti-pTyk2. The
tubes were incubated at room temperature protected
from light for 1 h, and then cells were pelleted and re-
suspended in Perm/Wash Buffer. Tubes containing the
anti-pJAK1, anti-pJAK2, or anti-pTyk2 were supple-
mented with PE-conjugated secondary antibody, and
tubes containing anti-pJAK3 were supplemented with
PerCP-conjugated secondary antibody. The anti-CD4-
and anti-CD8-containing tubes, as well as the anti-
CD19-containing tubes, were also supplemented with
the T-cell marker antibody anti-CD3-PerCP (for anti-
pJAK1, anti-pJAK2, and anti-pTyk2 tubes) or anti-CD3-
PE (for anti-pJAK3 tubes). Following incubation at room
temperature protected from light for 40 minutes, cells
were washed in Perm/Wash Buffer and suspended in
Stain Buffer (BD Biosciences). The samples were kept on
ice for a maximum of 3 h until flow cytometric
acquisition.
Flow cytometry
Flow cytometric data were acquired using a BD FACS-
Canto II flow cytometer and analyzed with BD FACS-
Diva software (BD Biosciences), as described previously
[14]. CD3+CD4+ and CD3+CD8+ T lymphocytes, CD19+
B lymphocytes, and CD14+ monocytes were identified,
and pJAK1-PE, pJAK2-PE, pJAK3-PerCP, and pTyk2-PE
fluorescence intensities of the respective cell populations
were determined as relative fluorescence units (RFU).
Statistical analysis
The data are presented as means with SDs and numbers
of patients with percentages, and groups were compared
using a permutation test or chi-square test. Exact logistic
regression was used to investigate crude and adjusted re-
lationships of the study entry variables to remission at
12 months. The 95% CIs of means were estimated by
bias-corrected bootstrapping (5000 replications). pJAK1-
PE, pJAK2-PE, pTyk2-PE, and pJAK3-PerCP fluorescence
intensities are presented as standardized fluorescence in-
tensities (mean 0, SD 1) of RFU. Correlation coefficients
were calculated by the Spearman method using Šidák-ad-
justed probabilities. The Stata 14.1 statistical software
package (StataCorp, College Station, TX, USA) was used
for the analyses.
Results
Treatment and outcome
The study included 35 DMARD-naïve patients with
recent-onset RA (Table 1). After blood sampling, 33 pa-
tients started sDMARD therapy (methotrexate, sulfasala-
zine, hydroxychloroquine) according to the Finnish
national care guidelines [4] (Table 1). In addition, 16 pa-
tients (46%) started a course of low-dose (≤10 mg/day)
oral prednisone. Intra-articular glucocorticoid injections
were also applied to treat swollen joints according to the
Finnish national guidelines [4].
During follow-up (mean duration 12 months, SD
3.6 months), the drug treatment was modified when ap-
propriate, targeting remission. After follow-up, 33 pa-
tients (91%) were on sDMARDs, including 3 patients
(9%) on oral prednisone. Twenty patients (57%) were in
remission (no swollen or tender joints, and normal
ESR). No patients were on biological DMARDs. The pa-
tients in remission started with a lower DAS28 score,
lower number of tender joints, and lower patient global
assessment at study entry (Table 1).
Phosphorylation levels of JAKs
Baseline phosphorylation of levels of JAKs were com-
pared between the patients who subsequently were in re-
mission after 12-month follow-up and the patients who
were not (Fig. 1). JAK3 phosphorylation in CD8+ and
CD4+ T cells and CD19+ B cells was found to be higher
in the patients who achieved remission than in those
who did not (p values of 0.015, 0.024, and 0.038, respect-
ively). No correlations were found between baseline JAK
phosphorylation levels and plasma ESR or plasma CRP
levels (data not shown).
In order to further elucidate the predictive value of
JAK phosphorylation in each cell population, crude and
adjusted exact logistic regression models of the baseline
phosphorylation levels of JAK1, JAK2, JAK, and Tyk2
were constructed (Table 2). In the models adjusted for
anti-cyclic citrullinated peptide, number of DMARDs
started at entry, smoking, and white blood cell count,
high phosphorylation level of JAK3 was associated with
remission in all leukocyte types studied. In addition, low
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JAK2 phosphorylation level in CD14+ monocytes at
baseline emerged to be associated with remission.
Tyk2 phosphorylation level was higher in patients than
in healthy reference subjects in all leukocyte types stud-
ied (Table 3): CD4+ T cells (p = 0.0014), CD8+ T cells (p
= 0.037), CD19+ B cells (p = 0.049), and CD14+ mono-
cytes (p < 0.001). This indicated constitutive activation of
Tyk2 in the patients’ circulating leukocytes. Also, JAK2
phosphorylation of CD14+ monocytes was higher in pa-
tients than in healthy reference subjects (p = 0.011)
(Table 3).
Discussion
The results of the present study show that high baseline
JAK3 phosphorylation in all peripheral blood leukocyte
subtypes studied (i.e., CD4+ and CD8+ T cells, B cells,
and monocytes) is associated with remission achieved by
sDMARDs among patients with early untreated RA. The
JAK signaling profile of the patients who turned out as
good sDMARD responders also included low JAK2
phosphorylation in CD14+ monocytes. Although there is
evidence of JAK activation within inflamed joints ob-
served in a few studies using animal models [15] or syn-
ovial cells from patients with RA [16–18], there are no
prior studies, to the best of our knowledge, on the phos-
phorylation of JAKs in peripheral blood leukocytes of
patients with RA. Consequently, the potential of the JAK
phosphorylation profile in leukocytes as a predictor of
treatment response in RA has not been studied before.
There are a number of possible explanations for the
association we found between baseline JAK3 phos-
phorylation level and treatment response. First, the
sDMARDs used can be effective in downregulating
JAK3-involving inflammatory pathways, although the
detailed mechanisms remain to be elucidated. In this
context, it may be noteworthy that JAK3 cannot be
replaced by other JAKs in transducing signals from
the receptors of interleukin (IL)-2, IL-4, IL-7, IL-9,
IL-15, and IL-21 (γc receptors) [7]. These cytokines
are among those whose levels in peripheral blood are
affected by DMARDs [19–22], which may represent a
disease-modifying mechanism involving JAK3 signal-
ing. Second, the anti-inflammatory or regulatory pro-
cesses that are also triggered by JAK3 can possibly
facilitate the amelioration of RA. It has been observed
that JAK3 signaling limits T-helper cell type 17 differ-
entiation in CD4+ T cells [23], maintains circulating
quiescent T cells [24], and negatively regulates the
production of inflammatory cytokines in innate im-
mune cells [25, 26]. In fact, in developing kinase in-
hibitor therapies for the treatment of RA, the
challenge is to halt the pathogenic effects while pre-
serving the homeostatic and advantageous effects of
the kinases [27].
Table 1 Baseline characteristics of the patients categorized according to remission at 12-month follow-up
Variable All patients (n = 35) Remission at follow-up p Valuea
No (n = 15) Yes (n = 20)
Age, years, mean (SD) 55 (14) 57 (15) 53 (14) 0.43
Female sex, n (%) 28 (80%) 15 (75%) 13 (87%) 0.39
Rheumatoid factor-positive, n (%) 26 (74%) 10 (67%) 16 (80%) 0.37
Anti-citrullinated protein antibody-positive, n (%) 27 (77%) 10 (67%) 17 (85%) 0.20
Smokers, n (%) 8 (23%) 5 (33%) 3 (15%) 0.20
Duration of symptoms, months, mean (SD) 6 (7) 6 (10) 6 (4) 0.89
Number of tender joints, 0–68, mean (SD) 7 (6) 10 (7) 6 (5) 0.040
Number of swollen joints, 0–66, mean (SD) 6 (5) 6 (4) 7 (6) 0.78
Erythrocyte sedimentation rate, mm/h, mean (SD) 19 (15) 22 (18) 16 (13) 0.32
Plasma C-reactive protein, mg/L, mean (SD) 7 (7) 6 (3) 8 (9) 0.41
White blood cell count, ×109/L, mean (SD) 6.9 (2.4) 7.5 (3.1) 6.5 (1.6) 0.23
Patient global assessment, 0–100-mm VAS, mean (SD) 40 (25) 54 (24) 31 (21) 0.0073
DAS28 score, mean (SD) 3.63 (1.14) 4.08 (1.19) 3.29 (1.01) 0.040
Number of DMARDs started, mean (range) 2.2 (0–3) 2.1 (1–3) 2.3 (0–3) 0.72
Single DMARD, n 4 2 2
Combination of two DMARDs, n 13 9 4
Combination of three DMARDs, n 16 4 12
None, n 2 0 2
Abbreviations: VAS Visual analogue scale, DAS28 28-Joint Disease Activity Score, DMARD Disease-modifying antirheumatic drug
a Significance of difference between No and Yes groups calculated using permutation test or chi-square test
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Table 2 ORs for remission after 1 year of follow-up
Model Variable CD8+ T cells CD4+ T cells CD19+ B cells CD14+ monocytes
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Unadjusted pJAK1 0.57 (0.25–1.18) 0.14 0.47 (0.18–1.03) 0.053 0.75 (0.36–1.49) 0.42 0.78 (0.38–1.56) 0.49
pJAK2 0.96 (0.48–1.89) 0.90 0.63 (0.30–1.26) 0.20 0.95 (0.48–1.88) 0.88 0.55 (0.25–1.10) 0.092
pJAK3 3.01 (1.20–9.55) 0.017 2.40 (1.08–6.11) 0.032 2.19 (1.03–5.32) 0.044 1.84 (0.91–4.00) 0.094
pTyk2 1.34 (0.64–3.24) 0.49 1.23 (0.61–2.84) 0.61 1.46 (0.65–3.78) 0.44 0.92 (0.46–1.82) 0.80
Adjusteda pJAK1 0.42 (0.13–1.14) 0.083 0.46 (0.16–1.09) 0.077 0.68 (0.30–1.49) 0.32 0.84 (0.36–1.94) 0.70
pJAK2 0.97 (0.46–2.1) 0.94 0.53 (0.25–1.20) 0.14 0.66 (0.29–1.42) 0.29 0.42 (0.16–0.96) 0.034
pJAK3 3.87 (1.33–16.65) 0.009 2.73 (1.16–7.90) 0.017 2.87 (1.11–8.87) 0.029 2.22 (1.01–5.31) 0.045
pTyk2 1.40 (0.64–3.25) 0.45 1.32 (0.62–3.05) 0.52 1.47 (0.63–3.47) 0.44 0.92 (0.45–1.93) 0.83
pJAK Phosphorylated Janus kinase, Tyk Tyrosine kinase
a The models are adjusted for anti-citrullinated protein antibody, number of disease-modifying antirheumatic drugs at entry, smoking, and white blood cell count.
ORs are calculated per 1 SD
Fig. 1 Baseline Janus kinase phosphorylation (pJAK) profiles of peripheral blood a CD8+ T cells, b CD4+ T cells, c CD19+ B cells, and d CD14+
monocytes according to remission at 12-month follow-up. Squares indicate group means, and whiskers indicate group 95% CIs. The fluorescence
intensities are standardized to controls (mean 0 and SD 1). Horizontal lines show controls’ means. Remission groups are compared using a
permutation test
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The association between low JAK2 phosphorylation in
monocytes and good treatment response may reflect the
critical roles of JAK2 in innate immune responses. It has
been demonstrated in monocytic cells that JAK2 inhib-
ition blunts the production of both early and late inflam-
matory mediators [28], and that the prolonged effect of
interferon-γ on lipopolysaccharide-induced tumor ne-
crosis factor production is apparently mediated by JAK2
[29]. It is noteworthy that the JAK inhibitor tofacitinib
has high affinity for JAK3, but it also inhibits JAK1 and,
to a lesser extent, JAK2, and also STAT1 and STAT3 [6].
Thus, the efficacy of tofacitinib in treating RA [6, 7, 30]
may actually be due to its effects on target molecules
other than JAK3. It has also been reported on the basis
of in vitro studies on rheumatoid synovial fibroblasts
that JAK3-selective inhibition is insufficient to control
the proinflammatory cascade, and inhibition of JAK1
and JAK2 may be needed instead [31].
It should be noted that because the patients’ JAK3
phosphorylation levels overlapped with those of healthy
reference subjects, they cannot serve as diagnostic
markers for RA. The phenomenon in which levels of a
marker distinguish patients with RA according to diver-
gent outcomes while not distinguishing patients from
healthy control subjects has recently been described for
other potential markers, including microRNAs [32].
Hence, JAK3 phosphorylation may serve as a surrogate
marker, and the possibility remains that markers that
discriminate patients with RA from healthy individuals
will be discovered along the same signaling pathway.
We also observed that, in contrast to the other JAKs,
Tyk2 phosphorylation in lymphocytes and monocytes of
patients with RA was significantly higher than in those
of healthy reference subjects. Because this phosphoryl-
ation was not associated with measures of disease activ-
ity or treatment response, the context of the finding
remains elusive. Tyk2, for its part, promotes interferon-γ
production [33] and can be activated by IL-13 [34].
Methotrexate treatment (which was an essential
sDMARD in our study) reduces the levels of both of
these cytokines in patients with RA [19]. So, it is pos-
sible that Tyk2 phosphorylation increases along with the
inflammatory processes during the development of RA
and decreases along with the amelioration achieved by
sDMARDs, but its effects are not directly related to clin-
ical manifestations of RA. Interestingly, genetic variants
of Tyk2 have been reported to protect against RA, sys-
temic lupus erythematosus, and possibly other auto-
immune diseases, such as inflammatory bowel disease
[35]. Accordingly, Tyk2 phosphorylation in patients with
early RA (as a consequence of either genetic factors or
pathogenetic processes) may be associated with in-
creased risk for development of RA, though not directly
correlating to disease activity.
The quite low number of subjects is a limitation of the
present study. The strengths of the study include the ad-
vantages of the phosphospecific whole blood flow cyto-
metric method we used. Blood samples were easily
obtained, and only a small volume of blood (a couple of
milliliters) was required. Also, ex vivo phosphorylation
Table 3 Baseline phosphorylatad Janus kinase fluorescence intensities in peripheral blood leukocytes of patients and healthy
reference subjects
Fluorescence Cell type Patients (n = 35) Healthy control subjects (n = 17) p Value
pJAK1-PE CD4+ T 385 (92) 335 (75) 0.054
CD8+ T 387 (89) 365 (79) 0.41
CD19+ B 549 (151) 497 (121) 0.23
CD14+ Mo 863 (240) 737 (193) 0.06
pJAK2-PE CD4+ T 4443 (1446) 3885 (1484) 0.20
CD8+ T 4282 (1792) 4016 (1761) 0.62
CD19+ B 7675 (3026) 6340 (2680) 0.12
CD14+ Mo 6571 (2703) 4727 (1674) 0.011
pJAK3-PerCP CD4+ T 823 (197) 773 (163) 0.37
CD8+ T 1350 (283) 1388 (396) 0.69
CD19+ B 1040 (214) 994 (213) 0.47
CD14+ Mo 2035 (442) 1976 (385) 0.65
pTyk2-PE CD4+ T 380 (144) 297 (41) 0.001
CD8+ T 342 (128) 287 (43) 0.037
CD19+ B 361 (177) 295 (51) 0.049
CD14+ Mo 1118 (342) 827 (228) <0.001
Abbreviations: pJAK Phosphorylated Janus kinase, Mo Monocyte, PE Phycoerythrin, PerCP Peridinin chlorophyll protein complex, Tyk Tyrosine kinase
The fluorescence intensities are shown as means (SDs) in relative fluorescence units, with p values calculated using a permutation test
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due to sample handling was minimized, and the proced-
ure was quick (within hours) and has been evaluated as
being applicable for rapid immune status determination
before starting immunomodulatory therapy in inflamma-
tory diseases [36]. If our results are confirmed in larger
studies, it is possible that JAK3 phosphorylation, either
alone or with other markers from, for example, the JAK-
STAT pathway, is able to serve as treatment response
marker in RA.
Conclusions
Baseline JAK phosphorylation profile in circulating leu-
kocytes of patients with early untreated RA is associated
with treatment response achieved with sDMARDs. High
JAK3 phosphorylation level in both CD4+ and CD8+ T
cells, in CD19+ B cells, and in CD14+ monocytes is a
promising predictor of good treatment response to
sDMARDs in RA.
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